BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in meta...
Idioma en
Índice central bibliográfico con relevancia, facetas, obras canónicas, holdings KBART y acceso consolidado.